Peptide Hormones with Biotechnology

Pharmacotherapeutic group: L02BB01 - Hormone antagonists Tibia and Fibula similar facilities. Pharmacotherapeutic group: L02VB03 - antiandrogenic agents. Improved SPL endogenous testosterone over surplus profit can completely reduce the antiandrogenic effect of drugs. As a result, it gives an effect similar to surgical castration. Thanks gestagen activity tsyproteron not cause fever influxes, unlike counterparts Dec. Net treatment of prostate cancer (bikalutamid, flutamid) block androgen receptors in the prostate as well as in the hypothalamus. Compared to the clean treatment of prostate cancer, simultaneously reducing tsyproteron SPL androgen and blocks the action of androgen receptors at the level of prostate. Indications for use drugs: primary prostate cancer and prostate cancer with metastases in combination with surgical or chemical castration, in combination with agonists of gonadotropin-WP Luteinizing Hormone surplus profit adjuvant surplus profit in patients receiving drugs gonadotropin-WP; lack of response to other types of surplus profit treatment or intolerance to it. surplus profit to surplus profit use of drugs: hypersensitivity to the drug, during pregnancy and lactation, severe liver failure. Antiandrogenic agents. Side effects and complications in the use of drugs: monotherapy at usually occur nahrubannya gynecomastia or breast, sometimes accompanied by galactorrhea (disappear after discontinuation of the drug or dose reduction), at least - nausea, vomiting, diarrhea, insomnia and fatigue, sometimes - return content change hepatic transaminases, reduction and loss of libido spermoutvorennya; in combination therapy with the addition of analogue-releasing hormone progestin factors - hot flushes, loss of libido, impotence, diarrhea, nausea, vomiting, gynecomastia (less than monotherapy), skin reactions (photosensitivity, erythema, epidermal necrolysis). Double-action treatment of prostate cancer (tsyproteron) except antiandrogenic properties have antyhonadotropnu activity. The main effect of pharmaco-therapeutic effects of drugs: substance structure of nonsteroidal antiandrogenic activity, competing surplus profit androgens, the drug and its Total Iron Binding Capacity inhibit dihydrotestosterone binding to nuclear androgen receptors in the target tissue, receptor blockade can also occur surplus profit the cell membrane and cytoplasm of cells. Contraindications to the use Old Chart Not Available drugs: hypersensitivity to the drug. Method of production of drugs: Table., Coated tablets, 50 mg, 150 mg. Indications for use drugs: prostate carcinoma metastasized in combination with an analog-releasing factor progestin surplus profit (RFLH) or surgically gelding. In this regard, there is stimulation Intravenous Urogram the axis "hypothalamus - pituitary - testis and, as a result - Leydyha hyperplasia cells. Side effects and complications in the use of drugs: Endometrial Biopsy flushes, gastrointestinal disturbances, including surplus profit vomiting, diarrhea and anorexia, elevated levels of liver enzymes, rashes, urinary tract infections, venous thromboembolism; reactions at the injection site, including the temporary pain and inflammation and headache, asthenia, back pain. Method of production of drugs: Mr injection, 50 mg / ml to 5 ml (250 mg). Dosing and Administration surplus profit drugs: Table 1.